Programme

Pre-Conference
General Session
Symposium
State-of-the-Art Lecture
Industry Symposium
Workshops
13:00 – 18:00 Pre-Conference Workshop: Perspective for Precision Medicine in HCC
Chairs: Sandrine Faivre, MD, PhD (France), Peter Schirmacher, MD, PhD (Germany) and Augusto Villanueva, MD, PhD (USA)
13:00 – 13:25
  • (Morpho-)Molecular Subtyping of Liver Cancer and its Clinical Implications
    Lewis Roberts, MD, PhD (USA)
13:25 – 13:50
  • Biomarker Approaches for Loco-Regional Therapy
    Valérie Paradis, MD, PhD (France)
13:50 – 14:15
  • Biomarkers for Patient Selection in Systemic Liver Cancer Therapy
    Peter Schirmacher, MD, PhD, (Germany)
14:15 – 14:40
  • Preclinical Experimental Models to Improve Precision Medicine in Liver Cancer
    Lijian Hui, PhD (Peoples’ Republic of China)
14:40 – 15:00
  • Liquid Biopsy: Does it Provide Information to Tailor HCC Therapy?
    Augusto Villanueva, MD, PhD (USA)
15:00 – 15:20
  • Panel Discussion
15:20 – 15:40

Session Break

15:40 – 16:05
  • Precision medicine in HCC: What do the Guidelines Say?
    Fabio Piscaglia, MD, PhD (Italy)
16:05 – 16:30
  • Novel Systemic Therapies in HCC: What to Use, When and Why?
    Tim Meyer, MD, PhD (United Kingdom)
16:30 – 16:55
  • Immunotherapy and Immune-Based Biomarkers in Liver Cancer
    Bruno Sangro, MD, PhD (Spain)
16:55 – 17:20
  • Upcoming Systemic Treatment Approaches for Liver Cancer
    Josep M. Llovet, MD, PhD (Spain/USA)
17:20 – 17:55
  • Comprehensive Cancer Center Based Interdisciplinary Approaches to Liver Cancer
    Sandrine Faivre, MD, PhD (France)
17:55 – 18:15
  • Panel Discussion

The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.

18:30 – 19:30 Young Investigator Session
Chair: Maria Reig, MD, PhD (Spain)
08:00 – 09:30 ILCA Symposium 1: From Metabolic Syndrome to NASH and HCC
Chairs: Valérie Paradis, MD, PhD (France) and Lijian Hui, PhD (People’s Republic of China) 

  • Role of Autophagy in Metabolic Syndrome and Liver Carcinogenesis
    Anna Cuervo, MD, PhD (USA)
  • Involvement of Adaptive Immune Cells in NASH and NASH-HCC Transition
    Mathias Heikenwälder, MD, PhD (Germany)
  • Modulating Metabolic Syndrome to Decrease Tumour Occurrence
    Jean-François Dufour, MD, PhD (Switzerland)
09:30 – 10:15

State-of-the-Art Lecture 1: Future Anti-Cancer Therapeutic Targets: Put the Cart Before the Horses?
Speaker: Tak Wah Mak, PhD (Canada)

10:15 – 10:45 Coffee and Networking Break
10:45 – 11:00 Welcome Address
Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Bruno Sangro, MD, PhD (Spain) and Richard Finn, MD (USA)
11:00 – 12:30 General Session 1: Molecular Pathogenesis
6 oral communications selected from abstract submissions
12:30 – 12:45 Session Break
12:45 – 14:15 Industry Partner Lunch Symposium
14:15 – 14:30 Session Break
14:30 – 16:00 General Session 2: Clinical Trials
6 oral communications selected from abstract submissions
16:00 – 16:30 Coffee and Networking Break
16:30 – 18:00 ILCA Symposium 2: Heterogeneity in HCC
Chairs: Amaia Lujambio, MD (USA) and Michiie Sakamoto, MD, PhD (Japan)

  • Histological and Molecular Heterogeneity
    Michael S. Torbenson, MD (USA)
  • HCC Heterogeneity Using Conventional and Functional Imaging
    Jordi Rimola, MD (Spain)
  • How to Target and Monitor HCC Heterogeneity in Clinical Trials?
    Ann Lii Cheng, MD, PhD (Taiwan)
18:00 – 19:00

Welcome Reception

07:30 – 08:30 Industry Partner Symposium
08:30 – 10:00 General Session 3: Epidemiology and Risk Factors
Chairs: Masatoshi Kudo, MD, PhD (Japan) and Sasan Roayaie, MD (USA)
6 oral communications selected from abstract submissions
10:00 – 11:00 Networking Break and e-Poster Viewing Tour
11:00 – 12:30

Presidential Session
Chairs: Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Bruno Sangro, MD, PhD (Spain), Richard Finn, MD (USA)

  • Presidential Note
  • Nelson Fausto Award
  • Junior Investigator Awards
  • 4 oral communications selected from abstract submissions
12:30 – 12:45 Session Break
12:45 – 13:45 Industry Partner Lunch Symposium
13:45 – 14:00 Session Break
14:00 – 15:30 General Session 4: Treatment and Response
Chairs: Maria Reig, PhD (Spain) and Ann Lii Cheng, MD, PhD (Taiwan)
6 oral communications selected from abstract submissions
15:30 – 16:00 Coffee and Networking Break
16:00 – 17:30 ILCA Symposium 3: Debates

  • Liver Resection is Better than Radiofrequency
    • PRO: Kim Olthoff, MD (USA)
    • CON: Olivier Seror, MD, PhD (France)
  • Y90 Plays a Role in Advanced HCC
    • PRO: Laura Kulik, MD (USA)
    • CON: Jordi Bruix, MD, PhD (Spain)
  • Systemic Adjuvant Treatment for Intrahepatic Cholangiocarcinoma
    • PRO: John Primrose, MD (United Kingdom)
    • CON: Katie Kelley, MD (USA)
ILCA Single Topic Workshops (STW)
17:30 – 18:30 STW 1: Molecular Diversity in HCC
Liquid Biopsy in HCC: Strengths and Limitations
Chairs: Augusto Villanueva, MD (USA) and Irene Ng, MD, PhD (Hong Kong)
17:30 – 18:30 STW 2: Systemic Therapy
How to Sequence Treatment
Chairs: Andrew Zhu, MD, PhD (USA) and Bristi Basu, MD, PhD (UK)
17:30 – 18:30 STW 3: Surgery for Primary Liver Cancer
Transplantation for Cholangiocarcinoma
Chairs: Gonzalo Sapisochin, MD, PhD (Canada) and Lewis Roberts, MD, PhD (USA)
17:30 – 18:30 STW 4: Radiology
Integration of LI-RADS in Clinical Practice
Chair: Riccardo Lencioni, MD (Italy/USA) and Tae Kyoung Kim, MD, PhD (Canada)
17:30 – 18:30 Workshop for Nurses

  • Introduction by Chair
    Donna O’ Sullivan (United Kingdom)
  • Developing an Interactive Nurse-Led Clinic
    Sarah Selemani  (United Kingdom)
  • Management of the Patient on Immunotherapy
    Liz Gifford (United Kingdom)
  • Recent Developments in the Management of HCC
    Yuk Ting Ma, PhD (United Kingdom)
  • Open Forum with Speakers
18:30 – 19:30 Industry Partner Workshops
08:00 – 09:00 Industry Partner Symposium
09:00 – 10:00 Joint HCC UK / ILCA Grand Rounds Session
Chair: Aileen Marshall, PhD (United Kingdom)
Multidisciplinary case presentations and discussions
10:00 – 10:45
State-of-the-Art Lecture 2: Systemic Therapy for HCC: Is there a Standard of Care?
Chair: Andrew Zhu, MD, PhD (USA)
Speaker: Richard Finn, MD (USA)
10:45 – 11:00 Coffee and Networking Break
11:00 – 12:30 General Session 5: Novel Targets and Markers
6 oral communications selected from abstract submissions
12:30 – 12:45 Closing Ceremony
12:45 – 13:00 Session Break
13:00 – 13:45 General Assembly